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Abstract
Mitochondria play a crucial role in pathways of stress conditions. They can be transported from one cell to another, bringing their features to the
cell where they are transported. It has been shown in cancer cells overexpressing multidrug resistance (MDR) that mitochondria express proteins
involved in drug resistance such as P-glycoprotein (P-gp), breast cancer resistant protein and multiple resistance protein-1. The MDR phenotype
is associated with the constitutive expression of COX-2 and iNOS, whereas celecoxib, a specific inhibitor of COX-2 activity, reverses drug resis-
tance of MDR cells by releasing cytochrome c from mitochondria. It is possible that COX-2 and iNOS are also expressed in mitochondria of cancer
cells overexpressing the MDR phenotype. This study involved experiments using the human HCC PLC/PRF/5 cell line with and without MDR phe-
notype and melanoma A375 cells that do not express the MDR1 phenotype but they do iNOS. Western blot analysis, confocal immunofluores-
cence and immune electron microscopy showed that iNOS is localized in mitochondria of MDR1-positive cells, whereas COX-2 is not. Low and
moderate concentrations of celecoxib modulate the expression of iNOS and P-gp in mitochondria of MDR cancer cells independently from inhibi-
tion of COX-2 activity. However, A375 cells that express iNOS also in mitochondria, were not MDR1 positive. In conclusion, iNOS can be localized
in mitochondria of HCC cells overexpressing MDR1 phenotype, however this phenomenon appears independent from the MDR1 phenotype occur-
rence. The presence of iNOS in mitochondria of human HCC cells phenotype probably concurs to a more aggressive behaviour of cancer cells.
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Introduction
P-glycoprotein (P-gp), multidrug-resistant protein 1 (MRP1) and
breast cancer resistant protein (BCRP) are membrane proteins
belonging to the family of multidrug-resistant (MDR) proteins that
mediate intrinsic and acquired drug resistance in cancer cells. Malig-
nant tumours that possess the MDR phenotype are more resistant to
several unrelated anticancer drugs, such as doxorubicin, vinca alka-
loids, taxanes and others, and cause chemotherapy failure. The MDR
phenotype is a complex phenomenon and these proteins, also called
ABC transporters, mainly expressed in the plasma membrane and act-
ing by reducing the intracellular drug concentration, are mediators of
the phenotype. Nevertheless, the functions of P-gp, MRP1 and BCRP
are probably multiple, with some of them still unknown. It must also
be remembered that these proteins are also expressed in several nor-
mal tissues such as liver, kidney, gastrointestinal tract, placenta and
blood–brain barrier, where they play an important role in the physiol-
ogy of these tissues, by protecting them from toxic xenobiotics and
endogenous metabolites [1–3].
In recent years, the localization of these proteins on the nuclear
envelope and on the membrane of cytoplasmic organelles, such as
#These authors contributed equally to this work.
$This paper is dedicated to the dear memory of Lucia Formigli who has
passed away on March 18th, 2014.
*Correspondence to: Dr. Chiara SASSOLI,
Dept. of Experimental and Clinical Medicine,
Section of Anatomy and Histology,
Largo Brambilla, 3, Firenze 50134, Italy.
Tel.: +390552758063
Fax: +390554379500
E-mail: chiara.sassoli@unifi.it
ª 2015 The Authors.
Journal of Cellular and Molecular Medicine published by John Wiley & Sons Ltd and Foundation for Cellular and Molecular Medicine.
This is an open access article under the terms of the Creative Commons Attribution License, which permits use,
distribution and reproduction in any medium, provided the original work is properly cited.
doi: 10.1111/jcmm.12528
J. Cell. Mol. Med. Vol 19, No 6, 2015 pp. 1410-1417
mitochondria and endoplasmic reticulum, has suggested their
involvement in several signalling pathways [4–10]. It has been shown
that P-gp activity is related to the expression of the inducible isoform
of the cyclooxygenase-2 (COX-2) enzyme. The cyclooxygenase path-
way plays an important role in the regulation of inflammation and
cancer, and COX-2 appears to be important in tumour growth, metas-
tasis process and tumour drug resistance [11, 12]. In addition, a rela-
tionship has been found between COX-2 and BCRP activity and
between COX-2 and MRP1 [13, 14]. We have demonstrated that
MDR1-positive cancer cells express constitutively COX-2 and that
celecoxib, a specific inhibitor of COX-2 activity, can reverse drug
resistance to apoptosis of these cells by a P-gp-dependent but COX-
2-independent mechanism in MDR1-positive cells [15, 16].
The occurrence of the MDR1 phenotype in cancer cells includes
the expression of inducible nitric oxide synthase (iNOS) and produc-
tion of nitric oxide that is greater than that in a parental drug-sensitive
cell line [15]. Higher expression of iNOS leads to increased angio-
genic activity of an MDR1-positive HCC cell line, confirming the
observation that nitric oxide and proteins involved in drug resistance
such as P-gp, BCRP or MRP1, are linked to each other at least in this
cancer cell line [17–19].
Nitric oxide is a small highly reactive lipophilic molecule that regu-
lates several pathophysiological processes inside the cells. It can eas-
ily diffuse in water and also through cell membranes and its high
reactivity limits its half-life in biological fluids, influencing its localiza-
tion, concentration and duration of activity [20]. The complexity of its
biological effects explains the controversial results obtained by differ-
ent research groups. Nitric oxide regulates cell respiration, inhibits
cytochrome C oxidase, and reduces O2 consumption [21]. Nitric oxide
produced in normal conditions by the constitutive NOS isoforms,
nNOS and eNOS, does not reach concentrations that can significantly
inhibit respiration. However, iNOS can produce high amounts of nitric
oxide and for prolonged periods of time, damaging a variety of cellu-
lar targets and leading to apoptosis and mutagenesis [21].
The role of nitric oxide in apoptosis is controversial as it can be
pro-apoptotic or anti-apoptotic [22]. It has been shown that nitric
oxide-dependent apoptosis (that probably has antitumour activity)
requires high concentrations of nitric oxide while low concentrations
of it can protect cells from undergoing apoptosis, likely favouring
tumour growth [23]. It must be said that nitric oxide can regulate two
vital cell processes: energy production and apoptosis, and in both
pathways mitochondria play a crucial role [24, 25].
For these reasons, we decided to study whether P-gp and BCRP,
both involved in conferring drug resistance, are expressed in mito-
chondrial proteome. The mitochondrial proteome includes several
proteins of unknown function [26]. We have demonstrated that P-gp
and BCRP are overexpressed and functionally active in the mitochon-
drial cristae of an MDR1-positive cancer cell line, and Roundhill et al.
have shown the presence of MRP1 with efflux activity in human mito-
chondria [4, 6, 9]. The observation that P-gp, BCRP and MRP1 are
localized also in mitochondria of MDR1-positive cancer cells could
explain why drug-resistant cells do not release cytochrome c into
cytosol and the P-gp mediated celecoxib-induced apoptosis [16, 27].
Taken together, these findings suggest that the presence of the most
important drug-resistant proteins in mitochondria of MDR1 cancer
cells is not casual but causative. As mitochondria are involved in cell
apoptosis, it is possible to postulate that COX-2 and iNOS are
expressed in these organelles. This study addresses the question of
whether COX-2 and iNOS can be localized in mitochondria of MDR1
cancer cells and whether drugs that are known to affect apoptosis
can modulate their expression.
Materials and methods
Cell lines
Experiments were performed on a human HCC cell line PLC/PRF/5 [28] by
using parental drug-sensitive clone (P5) and the highly MDR1 subclone
(P1(0.5)). The P1(0.5) subclone was developed by prolonged serial expo-
sures to increasing concentrations of doxorubicin (DOX) (Santa Cruz Bio-
technology, CA, USA) starting from parental P5 cells, and subsequently
cultured in DMEM containing 0.5 lg/ml DOX and 10% foetal bovine
serum (FBS), as previously reported [15]. Confirmative experiments were
done in melanoma cell line A375 (American Type Culture Collection,
ATCC, Manassas, VA, USA) that express iNOS but do not express the
MDR1 phenotype. A375 cells were cultured in DMEM and 10% of FBS. All
cell lines were cultured at 37°C in an atmosphere containing 5% CO2.
Cell treatment
Because only some celecoxib (added to medium containing 10% FBS) is
not protein-bound and hence available for interacting on cells, we used
DOX-free, serum-free medium containing celecoxib in all experiments, as
described in the details for each experimental condition [29]. Cells were
seeded in complete medium for 24 hrs and then exposed to DOX-free,
serum-free medium containing 2.5, 5, 10, 20 or 50 lmol/l celecoxib
(Sigma-Aldrich, Milan, Italy). After 6 hrs, total proteins were extracted and
evaluated by Western Blot analysis. In other experiments, MDR1-positive
P1(0.5) HCC cells were exposed to DOX-free, serum-free medium contain-
ing 10–50 lmol/l celecoxib for 6 hrs and then were processed for confo-
cal immunofluorescence microscopy analysis and Western blot analysis.
Western blot analysis
Preparation of total protein lysates and Western blot analysis was per-
formed as previously described [15], using each of the following primary
antibodies: anti-COX-2 polyclonal antibody (Santa Cruz Biotechnology),
anti-P-gp (C219) monoclonal antibody (Gene Tex, Irvine, CA, USA), anti-
iNOS polyclonal antibody (Santa Cruz Biotechnology), anti-BCRP mono-
clonal antibody (Chemicon, Temecula, CA, USA), anti-apoptosis-inducing
factor (AIF-H300) polyclonal antibody (Santa Cruz Biotechnology), anti-
heat shock protein 60 (HSP-60) polyclonal antibody (Santa Cruz Biotech-
nology) and anti-b-actin monoclonal antibody (Sigma-Aldrich).
Preparation of mitochondrial fractions
Cells were washed (PBS, 39), resuspended in homogenization buffer
(HB; 150 mmol/l MgCl2, 10 mmol/l KCl, 10 mmol/l Tris, pH 6.7,
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protease inhibitors; 1 ml/1 9 107 cells), incubated on ice (15 min.),
and Dounce homogenized (35 strokes) (WCS: whole cell sample). HB
with sucrose (34.2%, 1/3 vol.) was added and centrifuged (‘low’ speed,
1000 9 g, 5 min., 4°C) to remove nuclei and unlysed cells. The pellet,
containing nuclei and unlysed cells (LSP: low speed pellet) was resus-
pended in mitochondrial suspension buffer (250 mmol/l sucrose,
10 mmol/l Tris, pH 7.0 with protease inhibitors). The supernatant was
centrifuged (‘medium’ speed, 5000 9 g, 10 min., 4°C), the pellet (CM:
crude mitochondria) was resuspended in HB + sucrose (20 ml), divided
into two samples and centrifuged (5000 9 g, 10 min., 4°C). One resul-
tant pellet was resuspended in Solution A (3 ml; 20 mmol/l HEPES,
1 mmol/l EDTA, 250 mmol/l sucrose, pH 7.4). Iodixanol solution (50%
iodixanol, 120 mmol/l HEPES, 6 mmol/l EDTA, 250 mmol/l sucrose, pH
7.4) was added (final concentration of 36%), placed in a centrifuge
tube, overlayed with Solution B (10 ml, 30% iodixanol, 80 mmol/l HE-
PES, 4 mmol/l EDTA, 250 mmol/l sucrose, pH 7.4), then Solution C (to
top, 10% iodixanol, 80 mmol/l HEPES, 4 mmol/l EDTA, 250 mmol/l
sucrose, pH 7.4), and centrifuged (50,000 9 g, 4 hrs, 4°C, swinging
bucket rotor). Protein was collected at the 30%/10% iodixanol interface,
an equal volume of Solution A (10 ml) was added, followed by centrifu-
gation (30,000 9 g, 10 min., 4°C). The resulting pellet was resus-
pended in mitochondrial suspension buffer (250 mmol/l sucrose,
10 mmol/l Tris, pH 7.0) with protease inhibitors (MFI: mitochondrial
fraction iodixanol). The second CM pellet was resuspended in resuspen-
sion buffer (RB = 10 mmol/l TRIS, 0.5 mmol/l EDTA, 10% glycerol, pH
7.5), applied to the top of a sucrose gradient (53.5% sucrose/43.5%
sucrose), centrifuged (5 hrs, 100,000 9 g, 4°C) and the resulting frac-
tion at the 53.5/43.5% sucrose interface was collected, diluted (RB, 1
vol.) and centrifuged (120,000 9 g, 1 hr, 4°C). The pellet was resus-
pended in TSNa buffer (10 mmol/l TRIS, pH 7.5, 50 mmol/l NaCl,
250 mmol/l sucrose) with protease inhibitors (MFS: mitochondrial frac-
tion sucrose) [30].
Confocal immunofluorescence
Living parental drug-sensitive P5, celecoxib untreated and treated
MDR1-positive P1(0.5) HCC cells and A375 melanoma cells grown on
glass coverslips were incubated for 30 min. at 37°C with 100 nmol/l of
MitoTracker red CMXRos (Molecular Probes Inc., Eugene, OR, USA), a
cell-permeable mitochondria selective dye, fixed in 0.5% buffered para-
formaldehyde for 10 min. at room temperature (RT) and then processed
for confocal immunofluorescence examination of iNOS. After permeabili-
zation with cold acetone for 3 min., washed cells were incubated in
blocking solution [0.5% bovine serum albumin (Sigma-Aldrich) and 3%
glycerol in PBS] for 30 min. and then with rabbit polyclonal anti-iNOS
(1:200; Santa Cruz Biotechnology) for 1 hr at RT. The immunoreactions
were revealed by incubation of the cells with goat anti-rabbit Alexa Fluor
488-conjugated IgG (Molecular Probes Inc.). Replacing the primary anti-
bodies with non-immune rabbit serum negative controls were carried
out; cross-reactivity of the secondary antibodies was tested in control
experiments in which primary antibodies were omitted. Finally, the cov-
erslips containing the immunolabelled cells were mounted with an antif-
ade mounting medium (Biomeda Gel mount, Electron Microscopy
Sciences, Foster City, CA, USA) and then viewed under a confocal Leica
TCS SP5 microscope (Leica Microsystems, Mannheim, Germany)
equipped with an HeNe/Ar laser source for fluorescence measurements.
The observations were performed with a Leica Plan Apo 63X/1.43NA oil
immersion objective. Series of optical sections (1024 9 1024 pixels
each; pixel size 204.3 nm), 0.4 lm in thickness, were taken through
the depth of the cells at intervals of 0.4 lm. Images were then pro-
jected onto a single ‘extended focus’ image. Qualitative assessment of
colocalization between iNOS and MitoTracker fluorescence signals was
performed by Image J colocalization Plugin Software (NIH, http://ima-
gej.nih.gov/ij/) and the quantitative analysis was done by calculating the
overlap coefficient (ranging from 0, minimum colocalization degree, to
1, maximum colocalization degree) using JACoP Plugin Image J [31].
At least 50 different cells were analysed in each experiment (n = 3).
Calculations were performed with GraPhPad Prism software program
(GraphPad, San Diego, CA, USA).
Immunogold electron microscopy
Cells were detached and centrifuged at 895 g for 10 min.; the pellets
were fixed in 4% PFA for 1 hr, dehydrated and embedded in Epon 812
A
B
Fig. 1 Expression of P-gp, COX-2, BCRP and iNOS in P5 and MDR1-
positive P1(0.5) cells. (A) Western blot analysis of P-gp, COX-2, BCRP
and iNOS expression in total cell lysate of P5 and P1(0.5) cells at basal
conditions. b-actin was used as a protein-loading control. (B) P-gp,
COX-2, BCRP and iNOS protein expression in different fractions of P1
(0.5) cells obtained during the preparation of mitochondria by differen-
tial centrifugation following purification on an iodixanol or sucrose gra-
dient as described in the Materials and methods section. WCS: whole
cell lysate; LSP: low speed pellets; CM: crude mitochondria; MFI: mito-
chondrial fraction iodixanol; MFS: mitochondrial fraction sucrose. AIF
and HSP-60 were used as mitochondrial marker proteins. One represen-
tative experiment out of three performed is shown.
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essentially as reported previously [6]. Ultra-thin sections collected on
nickel grids were etched with 30% hydrogen peroxide for 10 min., incu-
bated with normal goat serum (1:25 in TBS, pH 7.6; Sigma) for 15 min.
to quence a non-specific binding site and then with rabbit polyclonal
anti-iNOS (1:200; Santa Cruz Biotechnology) overnight at 4°C. After
washing in TBS (pH 7.6 and 8.2), the immunoreaction was revealed by
incubating the sections with anti-rabbit IgG antibodies conjugated with
10 nm colloidal gold particles [1:25 in TBS (pH 8.2), BB International,
Cardiff, UK] overnight at 4°C. Negative controls were carried out by
replacing the primary antibody with non-immune serum. Finally, the
ultra-thin sections were counterstained with uranyl acetate for 10 min.
and observed under a Joel 1010 (Jeol, Tokyo, Japan) transmission elec-
tron microscope at 80 kV.
Results
Expression of COX-2 and iNOS in mitochondrial
fractions in MDR1-positive P1(0.5) cells
Before studying the expression of COX-2 and iNOS in mitochondria,
we searched for the expression of P-gp, COX-2, BCRP and iNOS in
MDR1-positive P1(0.5) cells as compared to parental drug-sensitive
P5 cells (Fig. 1A). Western blot analysis shows the presence of
P-gp and BCRP in mitochondrial fractions of P1(0.5) cells (Fig. 1B).
In addition, it reveals that MDR1-positive P1(0.5) cells constitutively
express P-gp, COX-2 and iNOS proteins. These proteins were not
expressed in parental drug-sensitive P5 cells (Fig. 1A). BCRP, as
expected, was expressed both in parental-sensitive and MDR1 cell
lines, and it was slightly more expressed in P5 cells (Fig. 1A). To
investigate the presence of COX-2 and iNOS in mitochondria, pure
fractions of mitochondria were prepared by differential density gradi-
ent centrifugation using density media – iodixanol or sucrose (see
Materials and methods), and the fractions of each centrifugation
step were analysed by Western blot (Fig. 2A). AIF, a protein found
primarily in the mitochondria, was used as a marker for the purity
of mitochondrial preparations [32]. Data shown in this work confirm
the mitochondrial localization of P-gp and BCRP in MDR1 cancer
cells and, most importantly, show the presence of iNOS in mito-
chondrial fractions, whereas COX-2 was not expressed (Fig. 1B).
Mitochondrial localization of iNOS in MDR1-
positive P1(0.5) cells by confocal and electron
microscopy analyses
Confocal and immunoelectron microscopic analyses of the iNOS were
carried out to detect the precise subcellular localization of the protein
A B
C D
Fig. 2 Confocal immunofluorescence
analysis of mitochondrial localization of
iNOS in P5 and MDR1-positive P1(0.5)
cells. Representative confocal immunoflu-
orescence images of (A) P5 and (C)
MDR1-positive P1(0.5) cells grown on
glass coverslips, incubated with
100 nmol/l of MitoTracker red CMXRos to
label mitochondria (red), fixed and immu-
nostained for iNOS expression (green).
Note the colocalization between the two
fluorescent signals (yellow) indicating the
mitochondrial localization of the iNOS. (B
and D) Qualitative assessment of the colo-
calized points (white) obtained by using
Image J colocalization Plugin Software
(NIH). The images are representative of at
least three separate experiments with sim-
ilar results.
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in both parental drug-sensitive P5 and their derived MDR1-positive
P1(0.5) intact cells. Using confocal microscopy (Fig. 2), we found
that iNOS was robustly expressed in MDR1 P1(0.5) and parental
drug-sensitive P5 cell clones at level of plasma membrane and in the
cytoplasm with a clear mitochondrial localization. The results of the
colocalization analysis between the fluorescent signals relative to
iNOS and mitochondria, performed by using JACoP Plugin Image J
(NIH), indicated an overlap coefficient between the two signals of
0.475  0.05 in P5 and 0.524  0.01 in P1(0.5) cells, confirming
the expression of iNOS at the mitochondrial level. Immunoelectron
microscopy studies revealed that iNOS was localized at the level of
the mitochondrial cristae (Fig. 3).
Celecoxib modulates the expression of iNOS
To evaluate a possible association between P-gp expression and
BCRP or iNOS level in mitochondria of MDR1-positive P1(0.5) cells,
the expression of these proteins was determined in mitochondrial
fractions of P1(0.5) cells cultured for 6 hrs in a doxorubicin-free,
serum-free medium containing 2.5, 5, 10, 20 or 50 lmol/l celecoxib.
We have previously shown that 10 lmol/l celecoxib markedly reduced
the expression of P-gp, whereas 50 lmol/l did not affect P-gp expres-
sion in whole cell lysate of P1(0.5) cells [16]. Western blot analysis
clearly showed that the expression of P-gp and BCRP was reduced in
mitochondrial fractions of P1(0.5) cells treated for 6 hrs with 2.5 or
5 lmol/l celecoxib. On the contrary, the expression of iNOS was
increased under the same experimental conditions (Fig. 4). Cell expo-
sure to 10 lmol/l celecoxib reduced mitochondrial P-gp and iNOS
expression and did not alter the BCRP mitochondrial level (Fig. 4).
The higher concentrations of celecoxib, 20 or 50 lmol/l, did not mod-
ify the mitochondrial expression of P-gp, BCRP or iNOS in P1(0.5)
cells (Fig. 4). To complete the study of celecoxib effect on modulation
of iNOS expression in P1(0.5) cells, we tested the expression of iNOS
in total cell lysate of P1(0.5) cells cultured at basal condition and after
treatment with 10 or 50 lmol/l celecoxib for 6 hrs. Western blot
analysis showed that 10 lmol/l celecoxib reduced the iNOS expres-
sion in total cell lysate, whereas 50 lmol/l did not (Fig. 5A).
Confocal immunofluorescence analysis of iNOS expression in
MDR1-positive P1(0.5) cells confirmed the results obtained by Wes-
tern Blotting showing a decrease in the expression of the protein after
treatment with celecoxib 10 lM/l as compared to untreated cell,
whereas celecoxib 50 lM/l did not modify its expression (Fig. 5B, D
and F). The overlap coefficient between the fluorescent signals rela-
tive to iNOS and mitochondria did not vary upon celecoxib treatment
(0.52  0.07 in untreated and 0.51  0.04 in treated cells). These
data suggested that the decrease in iNOS expression induced by cel-
ecoxib correlates with a global decrease in iNOS expression rather
than with its intracellular distribution (Fig. 5C, E and G).
Mitochondrial localization of iNOS in iNOS-
positive A375 cells by Western blot and confocal
analyses
To determine whether the presence of iNOS on mitochondrial mem-
brane, as observed in our experiments, only affects P1(0.5) cells,
used in these experiments or it is a phenomenon occurring in other
iNOS-positive cells, we have determined the expression of iNOS on
mitochondrial membrane of melanoma A375 iNOS-positive cells.
Fig. 3 Immunoelectron cytochemistry analysis of iNOS protein in
MDR1-positive P1(0.5) cells. Representative transmission electron
microscopy image of Epon-812-embedded samples of MDR1-positive
P1(0.5) cells processed for immunogold labelling of anti-iNOS antibody.
The photograph shows a mitochondrion with the cristae decorated with
iNOS-gold particles (arrows). The image represents at least three sepa-
rate experiments with similar results.
Fig. 4 Effect of celecoxib on the expression of P-gp, BCRP and iNOS in
mitochondria of MDR1-positive P1(0.5) cells. Mitochondria of P1(0.5)
cells were purified by using the fraction methodology based on iodixa-
nol separation as described in the Materials and methods section. HSP-
60 were used as a protein-loading control. One experiment representa-
tive of the three performed is shown.
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Western blot analysis revealed the presence of iNOS in mitochondria
fractions of A375 cells (Fig. 6A). Confocal immunofluorescence
confirmed the results obtained by Western blot analysis, showing
the presence of iNOS on mitochondrial membrane of these cells
(Fig. 6B and C).
Discussion
These data show that human HCC cells that overexpress the MDR1
phenotype constitutively express iNOS in mitochondria as well as P-
gp, BCRP and MRP1 in comparison to their parental drug-sensitive
cells. The iNOS was expressed in the inner mitochondrial membrane
at the level of the cristae; in addition, it was possible to modulate its
expression by using drugs, such as the coxib inhibitor celecoxib.
However, celecoxib-induced changes of iNOS expression in mito-
chondria were not because of its inhibitory effect on COX-2 activity
but to unknown mechanism. It is possible to say that only low con-
centrations of celecoxib caused changes in iNOS expression, higher
concentration of the coxib, though inhibitory on the COX-2 activity,
had no effect of the expression of iNOS. Furthermore, these data
show that COX-2 was not expressed in mitochondria although it was
present in the cytosol of the same cells. In the same time, it must be
said that cells that constitutively express iNOS, as melanoma cells
A375, also express iNOS in mitochondria without being MDR1 posi-
tive and not expressing P-gp. According to us, this means that occur-
ring of MDR1 phenotype and iNOS expression in mitochondria are
not mutually linked.
A
B C
D E
F G
Fig. 5 Analysis of iNOS expression in
MDR1-positive P1(0.5) cells cultured at
basal condition (0) and after treatment
with 10 or 50 lmol/l celecoxib for 6 hrs.
(A) Western blot analysis of iNOS in total
cell lysate. b-actin was used as a protein-
loading control. (B–G) Representative con-
focal immunofluorescence images of
MDR1-positive P1(0.5) cells grown on
glass coverslips incubated with 100 nmol/
l of MitoTracker red CMXRos to label
mitochondria (red) fixed and immuno-
stained for iNOS expression (green). The
colocalization between the two fluorescent
signals (yellow) indicates the mitochon-
drial localization of the iNOS. In C, E, G,
qualitative assessment of the colocalized
points (white) between the two fluorescent
signals obtained by using Image J colo-
calization Plugin Software (NIH) is shown.
Note that the treatment with 10 lM/l cel-
ecoxib (D and E) reduced iNOS expression
as compared with the untreated cells (B
and C), whereas the treatment with
50 lM/l celecoxib (F and G) did not mod-
ify its expression. The localization of iNOS
at mitochondrial level did not vary upon
celecoxib treatment (C, E and G). The
images are representative of at least three
separate experiments with similar results.
ª 2015 The Authors.
Journal of Cellular and Molecular Medicine published by John Wiley & Sons Ltd and Foundation for Cellular and Molecular Medicine.
1415
J. Cell. Mol. Med. Vol 19, No 6, 2015
The expression of iNOS at the inner membrane level of the mito-
chondrial wall, where proteins are involved in the respiratory chain,
suggests a role of iNOS and its product nitric oxide in the transport of
electrons at this level. Nitric oxide, produced by the activity of iNOS,
is a lipophilic reactive compound with an unpaired electron that can
easily diffuse through cell membranes. For this reason, nitric oxide
can act inside the cell as a free radical, leading to oxidative stress
[21]. This increases reactive oxygen species (ROS) production, and
cell proliferation and minor O2 utilization by cells [21]. As cancer
frequently grows in hypoxic conditions in vivo, the expression of
iNOS at mitochondrial level is advantageous to cancer cells for sur-
vival in hypoxic conditions. ROS formation triggers cell proliferation,
so all together features of MDR1-overexpressing cancer cells create a
vicious circle where increased ROS formation and iNOS expression
enhance cancer cell proliferation, leading to hypoxia that causes
secretion of VEGF, hepatocyte growth factor and the hypoxia induc-
ible factor with the contemporary enhancement of the MDR1 gene
transcription [17, 21].
With regard to the modulation of iNOS expression, we observed
that low concentrations (2.5 or 5 lmol/l) of celecoxib, that inhibits
COX-2 activity, increases iNOS expression, and contemporarily
reduces P-gp and BCRP expression in mitochondria. Interestingly,
concentration of 10 lmol/l of celecoxib had the opposite effect on
iNOS expression, reducing its expression together with that of P-gp,
whereas even higher concentration of celecoxib (50 lmol/l) had no
effect on P-gp, BCRP or iNOS mitochondrial expression. These obser-
vations suggest that it is possible to modulate the expression of iNOS
in mitochondria by using drugs. They also suggest that celecoxib can
produce different effects on iNOS and P-gp expression, depending
upon its concentration. This phenomenon can explain controversial
results observed in cancer treatment. Clearly, the effect of celecoxib
on iNOS, P-gp and BCRP expression in addition to what we have
shown about its capacity to induce apoptosis in MDR1-positive can-
cer cells could be responsible for its reported anticancer effect [16,
33, 34].
These data also show that COX-2 is not expressed in the mito-
chondria of MDR1-overexpressing cancer cells, suggesting that the
enzyme is not involved in the regulation of iNOS, P-gp and BCRP
expression in mitochondria of these cells. COX-2 is constitutively
expressed in the cytosol of these cells, probably as they use prosta-
glandins as protective compounds in toxic environments. It was also
proposed that COX-2 could be involved in the regulation of P-gp
expression [12], although this does not seem to be the case in mito-
chondria [33–35].
Clearly, based on these data, it is possible to say that
expression of iNOS and occurrence of MDR1 phenotype in can-
cer cells are not necessarily linked each to other. Melanoma cell
line A375 that express iNOS in the cytosol and mitochondria do
not express P-gp and the MDR1 phenotype as shown here. Find-
ings of this work are in agreement with previous results where
we showed that celecoxib-induced apoptosis was because of the
inhibition of P-gp expression by a COX-2-independent mechanism
[16].
In conclusion, the idea that the MDR1 cancer cell phenotype is
only because of overexpression of proteins that transport anticancer
drugs outside cancer cells has changed somewhat. The expression of
proteins such as P-gp, BCRP, MRP1, iNOS and others in any cell
membrane, including mitochondria, is much more complex than what
was originally thought. This complexity explains the failure of all
attempts to overcome cancer cell resistance to any anticancer treat-
ment based on a single drug.
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Fig. 6 Analysis of expression of iNOS in A375 melanoma cells. (A) iNOS
protein expression in different fractions of A375 cells obtained during
the preparation of mitochondria by differential centrifugation following
purification on an iodoxanol or sucrose gradient as described in the
Materials and methods section. WCS: whole cell lysate; LSP: low speed
pellets; CM: crude mitochondria; MFI: mitochondrial fraction iodixanol;
MFS: mitochondrial fraction sucrose. AIF and HSP-60 were used as
mitochondrial marker proteins. One representative experiment out of
three performed is shown. (B) Representative confocal immunofluores-
cence images of A375 melanoma cells grown on glass coverslips, incu-
bated with 100 nmol/l of MitoTracker red CMXRos to label
mitochondria (red), fixed and immunostained for iNOS expression
(green). Note the colocalization between the two fluorescent signals
(yellow) indicating the mitochondrial localization of the iNOS and the
qualitative assessment of the colocalized points (white) obtained by
using Image J colocalization Plugin Software (NIH). The images are rep-
resentative of at least three separate experiments with similar results.
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